| 1. Coleman RE. (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity.. Clin Cancer Res, 12 (20 Pt 2): (6243s-6249s). [PMID:17062708] |
| 2. Stewart AF. (2005) Clinical practice. Hypercalcemia associated with cancer.. N Engl J Med, 352 (4): (373-9). [PMID:15673803] |
| 3. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH et al.. (2006) Denosumab in postmenopausal women with low bone mineral density.. N Engl J Med, 354 (8): (821-31). [PMID:16495394] |
| 4. Liu C, Chen X, Zhi X, Weng W, Li Q, Li X, Zou Y, Su J, Hu HG.. (2018) Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.. Eur J Med Chem, 145 (661-672). [PMID:29348072] |
| 5. Jiang M, Peng L, Yang K, Wang T, Yan X, Jiang T, Xu J, Qi J, Zhou H, Qian N, Zhou Q, Chen B, Xu X, Deng L, Yang C.. (2019) Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.. J Med Chem, 62 (11): (5370-5381). [PMID:31082234] |
| 6. Rinotas V,Papakyriakou A,Violitzi F,Papaneophytou C,Ouzouni MD,Alexiou P,Strongilos A,Couladouros E,Kontopidis G,Eliopoulos E,Douni E. (2020) Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.. J Med Chem, 63 (20.0): (12043-12059). [PMID:32955874] |
| 7. Wong, B R BR and 11 more authors.. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.. The Journal of biological chemistry, (3): [PMID:9312132] |
| 8. Anderson, D M DM and 9 more authors.. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.. Nature, (13): [PMID:9367155] |
| 9. Lacey, D L DL and 23 more authors.. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.. Cell, (17): [PMID:9568710] |
| 10. Nagai, M M, Kyakumoto, S S and Sato, N N.. (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.. Biochemical and biophysical research communications, (16): [PMID:10708588] |
| 11. Body, Jean-Jacques JJ and 14 more authors.. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.. Cancer, (1): [PMID:12548591] |
| 12. Melchert, Magda M and List, Alan A.. (2007) The thalidomide saga.. The international journal of biochemistry & cell biology, [PMID:17369076] |
| 13. Sobacchi, Cristina C and 20 more authors.. (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.. Nature genetics, [PMID:17632511] |
| 14. Lipton, Allan A and Jun, Susie S.. (2008) RANKL inhibition in the treatment of bone metastases.. Current opinion in supportive and palliative care, [PMID:18685421] |
| 15. Akobeng, Anthony K AK and Stokkers, Pieter C PC.. (2009) Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.. The Cochrane database of systematic reviews, (15): [PMID:19370685] |
| 16. Reuter, Simone S, Gupta, Subash C SC, Phromnoi, Kanokkarn K and Aggarwal, Bharat B BB.. (2012) Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.. British journal of pharmacology, [PMID:21955206] |
| 17. Luan, Xudong X and 8 more authors.. (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:22664871] |
ZJ23F1001443